Hypertrophic Cardiomyopathy Clinical Trial

Extended ECG Monitoring in HCM Patients

Summary

The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour monitoring.

View Full Description

Full Description

Optimal duration to monitor patients for identifying nsVT remains unclear. The investigators aim to determine the prevalence and burden of nsVT with longer term monitoring with the iRhythm Zio XT device over a 2-week period vs. 48 hours; and whether, this greater burden of nsVT compared to conventional shorter monitoring potentially identifies a subset of HCM patients who may be at higher risk of sudden cardiac death.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject must be 18 to 65 years of age at time of informed consent and must not be a member of a vulnerable population.
Subject has been diagnosed with hypertrophic cardiomyopathy, as defined by a maximal LV wall thickness of ≥15 mm anywhere in LV wall, in absence of another cause that could be responsible for the LV hypertrophy.
Subject eligible to receive the Zio XT device per the current approved indications for use.

Exclusion Criteria:

Subject with pacemaker
Known skin allergies or reaction to adhesives
The investigator deems a condition that could limit a subject's ability or unwillingness to participate in the study, comply with study required monitoring and/or follow-up visits.

Study is for people with:

Hypertrophic Cardiomyopathy

Estimated Enrollment:

250

Study ID:

NCT04056715

Recruitment Status:

Completed

Sponsor:

iRhythm Technologies, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Tufts Medical Center
Boston Massachusetts, 02111, United States

How clear is this clinincal trial information?

Study is for people with:

Hypertrophic Cardiomyopathy

Estimated Enrollment:

250

Study ID:

NCT04056715

Recruitment Status:

Completed

Sponsor:


iRhythm Technologies, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.